Pipeline

We are developing a differentiated portfolio of locally and systemically administered oncolytic virus therapies across our oncolytic Herpes Simplex Virus (oHSV) and our Synthetic Virus Platform. This will enable us to pursue multiple indications with the potential to help transform outcomes for more cancer patients.
Development Stage
Platform
Research
Ind-Enabling
Phase 1
Phase 2
Phase 3

oHSV

Intratumoral

ONCR-177

oHSV

Intratumoral

Key Attributes

  • Six i/o approaches in one:


    • oHSV
    • IL-12

    • FLT3LG

    • CCL4

    • anti-PD-1

    • anti-CTLA-4


  • Full replication competency

Indications
Breast
SCCHN
Melanoma
Other solid tumors
Commercial Rights

oHSV

Intratumoral

ONCR-GBM

oHSV

Intratumoral

Key Attributes

  • Multiple, innovative payloads

  • Safety and arming tailored to GBM

Indications
Glioblastoma multiforme
Other CNS tumors
Commercial Rights

Synthetic Virus

Intravenous

Coxsackievirus
A21 (CVA21)

Synthetic Virus

Intravenous

Key Attributes

  • Repeat IV dosing

  • Optimized strain


Indications
NSCLC
Melanoma
Bladder
Other solid tumors
Commercial Rights

Synthetic Virus

Intravenous

Seneca Valley
Virus (SVV)

Synthetic Virus

Intravenous

Key Attributes

  • Repeat IV dosing

  • Optimized strain

Indications
SCLC
Prostate and other endocrine tumors
Commercial Rights
Platform
Therapy
Key Attributes
Indications
Research
IND-enabling
Phase 1
Phase 2
Phase 3
Commercial Rights

oHSV

Intratumoral

ONCR-177

  • Six i/o approaches in one:


    • oHSV
    • IL-12

    • FLT3LG

    • CCL4

    • anti-PD-1

    • anti-CTLA-4


  • Full replication competency

Breast
SCCHN
Melanoma
Other solid tumors

Monotherapy and in Combination with

ONCR-177, our lead candidate, is an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy for the treatment of multiple solid tumor cancers. ONCR-177 fights tumors through multiple mechanisms, including inherent oncolytic activity, immune stimulation elicited by viral infection and the expression of five transgenes (IL-12, CCL4, FLT3LG, anti-PD-1 and anti-CTLA-4).

Learn more about our oHSV Platform.

Preclinical Findings

In preclinical studies, we have observed durable virus and immune system-driven anti-tumor activity in injected tumors as well as abscopal activity.  We have also observed that ONCR-177 is well tolerated in a validated animal safety model of oHSV when administered intravenously.

Learn more about our preclinical findings.

Development Status

We are currently enrolling patients in a Phase 1, open-label, multi-center, dose-escalation and expansion study designed to evaluate the safety and tolerability and to determine the recommended Phase 2 dose as well as preliminary anti-tumor activity of ONCR-177 alone and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors (ClinicalTrials.gov Identifier: NCT04348916).

For more information, please visit: https://clinicaltrials.gov/ct2/show/NCT04348916.

ONCR-GBM

  • Multiple, innovative payloads

  • Safety and arming tailored to GBM

Glioblastoma multiforme
Other CNS tumors

Leveraging our oHSV platform, we are pursuing an oncolytic virus immunotherapy, ONCR-GBM, to specifically target brain cancer, including glioblastoma multiforme. We are utilizing our knowledge of microRNA expression to engineer a microRNA attenuation strategy to protect healthy brain tissue and select a combination of payloads that address the specific drivers of immune suppression in brain cancer.

Development Status

We continue to conduct preclinical studies of ONCR-GBM and advance this program toward the clinic.

Learn more about our oncolytic Herpes Simplex Virus platform.

Synthetic Virus

Intravenous

Coxsackievirus
A21 (CVA21)

  • Repeat IV dosing

  • Optimized strain


NSCLC
Melanoma
Bladder
Other solid tumors

Our lead synthetic viral immunotherapy program is based on the coxsackievirus A21 (CVA21). We selected to advance a CVA21 product candidate based on a number of properties, including:

  • Demonstrated safety and tolerability after intravenous (IV) administration in patients
  • Ability to replicate in solid tumors, including lung tumors
  • Inability to insert into host chromosome, eliminating the potential of insertional mutagenesis

Learn more about our Synthetic Virus Platform, including our novel liquid nanoparticle (LNP) delivery strategy designed to overcome the challenges caused by neutralizing antibodies that have limited the efficacy of previous industry efforts to a treat tumors utilizing IV administration of CVA21. 

Development Status

In preclinical models, we have demonstrated proof of concept that our coxsackievirus A21 (CVA21)-based viral immunotherapy, when administered intravenously, is able to successfully deliver a synthetic viral genome to tumors leading to production of a replication-competent virus within the tumors that cause tumor growth inhibition.

We continue to conduct preclinical studies of our Synthetic Virus Platform and advance our lead Synthetic CVA21 clinical candidate toward the clinic.

Seneca Valley
Virus (SVV)

  • Repeat IV dosing

  • Optimized strain

SCLC
Prostate and other endocrine tumors

We are advancing a Seneca Valley Virus (SVV)-based synthetic virus program based on the acceptable safety and tolerability demonstrated by the intravenous (IV) administration of this virus in previously conducted early clinical trials.

Learn more about our Synthetic Virus Platform.

Our SVV-based viral immunotherapy program will utilize shared formulation and manufacturing strategies with our lead synthetic viral immunotherapy candidate (coxsackievirus A21, or CVA21, program) enabling efficiencies in product candidate development.

Development Status

In preclinical models, we have demonstrated proof of concept that our SVV-based viral immunotherapy, when administered intravenously, is able to successfully deliver a synthetic viral genome to tumors leading to production of a replication-competent virus within the tumors that cause tumor growth inhibition.

We continue to conduct preclinical studies of our SVV program. 

CNS = central nervous system; GBM = glioblastoma multiforme; IND = investigational new drug; I/O = immuno-oncology; NSCLC = non-small cell lung cancer; SCCHN = squamous cell carcinoma of the head and neck; SCLC = small cell lung cancer If you are interested in partnering with Oncorus, please contact us.
Top